Table I.
Distributions of AMH and age per participating study.
| Study | n | AMH, pmol/l (median (IQR)) | Age at blood collection, years (median (IQR)) |
|---|---|---|---|
| Studies contributing to summary statistics GWAS Ruth et al. (2019)a | |||
| Generations Study | 379 | 3.9 (0.8, 11.7) | 44 (40, 48) |
| Sister Study | 438 | 1.2 (0.1, 6.0) | 48 (45, 51) |
| Nurses’ Health Studies | 642 | 6.1 (2.0, 13.9) | 44 (41, 47) |
| Additional studies | |||
| Doetinchem Cohort Study | 2084 | 10.9 (2.9, 25.6) | 37.2 (31.2, 42.9) |
| ALSPAC mothers | 1885 | 2.0 (0.4, 5.2) | 46 (44, 49) |
| ALSPAC daughters | 1196 | 26.1 (18.2, 39.8) | 15.3 (15.3, 15.5) |
| SWAN | 425 | 1.1 (0.2, 3.3) | 47.3 (45.3, 49.3) |
| Total | 7049 | ||
a
In the original study ALSPAC mothers were included as well, but in the current analyses, summary statistics from ALSPAC were included separately to assess potential genomic inflation due to inclusion of both ALSPAC mothers and daughters. Therefore, we treated the ALSPAC mothers as individual study.
AMH, anti-Müllerian hormone; GWAS: genome-wide association analysis; SWAN, Study of Women’s Health Across the Nation.